- Home
- PROK vs ARQQ Comparison
PROK vs ARQQ Comparison
Compare PROK & ARQQ Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | PROK | ARQQ |
|---|---|---|
| Founded | 2015 | 2017 |
| Country | United States | United Kingdom |
| Employees | N/A | 91 |
| Industry | Biotechnology: Biological Products (No Diagnostic Substances) | Computer Software: Prepackaged Software |
| Sector | Health Care | Technology |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 296.8M | 250.9M |
| IPO Year | 2021 | N/A |
Fundamental Metrics
Financial Performance| Metric | PROK | ARQQ |
|---|---|---|
| Price | $1.88 | $14.51 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 5 | 1 |
| Target Price | $7.40 | ★ $60.00 |
| AVG Volume (30 Days) | ★ 1.0M | 344.4K |
| Earning Date | 05-08-2026 | 05-21-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $893,000.00 | N/A |
| Revenue This Year | N/A | $381.13 |
| Revenue Next Year | N/A | $212.00 |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | ★ 1075.00 | N/A |
| 52 Week Low | $0.54 | $11.52 |
| 52 Week High | $7.13 | $62.00 |
Technical Indicators
Market Signals| Indicator | PROK | ARQQ |
|---|---|---|
| Relative Strength Index (RSI) | 44.31 | 49.76 |
| Support Level | $1.71 | $11.72 |
| Resistance Level | $2.58 | $17.75 |
| Average True Range (ATR) | 0.12 | 1.20 |
| MACD | 0.01 | 0.16 |
| Stochastic Oscillator | 13.89 | 45.72 |
Price Performance
Historical ComparisonAbout PROK ProKidney Corp.
ProKidney Corp is a clinical-stage biotechnology company pioneering the development of a first-in-class, autologous cell therapy that is intended to preserve kidney function in patients with advance chronic kidney disease (CKD) and diabetes. Its product candidate, REACT (Renal Autologous Cell Therapy), is a disease-modifying cell therapy made from a patient's renal cells. REACT has the potential to slow and stabilize the progression of chronic kidney disease. The company's pipeline consists of the development program for severe diabetic kidney disease.
About ARQQ Arqit Quantum Inc.
Arqit Quantum Inc is a cybersecurity company that has pioneered a symmetric key agreement technology that makes the communications links of any networked device or data at rest secure against current and future forms of cyber attack - even an attack from a quantum computer. The company delivers its symmetric key agreement technology via its product SKA-Platform. The firm operates in one segment, that is, the provision of cybersecurity services. The company operates and generates its revenue from UK.